Clinical Trial Update: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating acalabrutinib plus rituximab as first-line treatment for mantle cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituximab (rituximab)

Snippet

Sponsor: University College, London | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING